Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

被引：0
作者：
Michael H. Schiff
Peter Sadowski
机构：
[1] University of Colorado,Division of Rheumatology
[2] Antares Pharma Inc.,undefined
来源：
Rheumatology International | 2017年 / 37卷
关键词：
Methotrexate; Subcutaneous; Rheumatoid arthritis; Dose conversion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Both the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines recommend the use of methotrexate (MTX) for the treatment of rheumatoid arthritis (RA) when there is no contraindication. While MTX is the foundation of RA therapy (Singh et al. in Arthritis Care Res 64:625–639,2012), absorption saturation compromises its oral bioavailability (BA). Differences in the relative BA of oral versus subcutaneous (SC) MTX demonstrate the need for guidance on successful dose-conversion strategies. This study was designed to compare MTX PK profiles as a result of MTX administration via three different treatment administrations: oral, SC MTX administered via an auto-injector (MTXAI) into the abdomen (MTXAIab) and into the thigh (MTXAIth). In this paper, we establish a dose-conversion method based on the BA of MTX from oral and SC administration. SC administration provided higher exposure of MTX than the same dose given orally. Unlike the exposure limitations of oral MTX, dose-proportional exposure was seen with SC MTX.
引用
收藏
页码：213 / 218
页数：5
相关论文
共 44 条
  • [1] Singh JA(2012)2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res 64 625-639
  • [2] Furst DE(2010)Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Ann Rheum Dis 69 964-975
  • [3] Bharat A(2006)The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26-37
  • [4] Smolen JS(2009)Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research Ann Rheum Dis 68 1100-1104
  • [5] Landewe R(1990)The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses Arthritis Rheum 33 1449-1461
  • [6] Breedveld FC(2013)Update on methotrexate as the anchor drug for rheumatoid arthritis Bull Hosp Joint Dis 71 S9-19
  • [7] Breedveld FC(2007)Quest-Ra: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries Ann Rheum Dis 66 1491-1496
  • [8] Weisman MH(2014)Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration Ann Rheum Dis 73 1549-1551
  • [9] Kavanaugh AF(2013)Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al Arthritis Care Res 65 1892-81
  • [10] Salliot C(2008)Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial Arthritis Rheum 58 73-622
12345